StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
000028.SZ$23.39-0.97%
Fair $23.39+0.0%

000028.SZ

China National Accord Medicines Corporation Ltd.

Healthcare / Medical DistributionShenzhen

$23.39

-0.23 (-0.97%)

Fairly Valued+0.0%Fair Value $23.39Fund rank 37/100 · Data gapFallback financials|
SA 46/C
F-Score: 6/9
Declining Revenue

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $2.6B · quality 81.3/100

Data gap 37/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 75/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

46/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 2 consecutive years
Thesis & Journal · 000028.SZLocal privado en este navegador · China National Accord Medicines Corporation Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$13.0B

P/E

11.9x

↓

EV/EBITDA

3.1x

↓

ROE

6.1%

↑

Gross Margin

10.7%

↓

Debt/Equity

0.23

↑
52-Week Range$23
$23$27

TradingView lightweight chart

000028.SZ price, volumen y niveles de valoración

Último $23.62Periodo +421.4%
Fair value: $23.39

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-0.0%

FCF CAGR

-14.0%

FCF margin

1.9%

FCF / Net income

1.25x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $73.42B · net income $1.14B · FCF $1.42B

2022-FY → 2025-FY

Gross margin

10.7%-1.5% pts

Operating margin

2.5%-0.8% pts

Net margin

1.5%-0.5% pts

FCF margin

1.9%-1.1% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$73.42B$73.42B$74.38B$75.48B$73.44B
Net Income$1.14B$1.14B$642.5M$1.60B$1.49B
EBITDA$3.06B$3.06B$2.49B$4.15B$3.88B
EPS2.042.041.152.872.67
Gross Margin10.7%10.7%11.1%12.0%12.2%
Operating Margin2.5%2.5%2.3%3.3%3.3%
Net Margin1.5%1.5%0.9%2.1%2.0%
Balance Sheet
Debt/Equity0.230.230.300.290.22
Current Ratio1.561.56———
Cash Flow
Free Cash Flow$1.42B$1.42B$2.99B$2.61B$2.24B
Returns
ROE6.1%6.1%3.6%9.2%9.2%
Valuation
P/E11.8711.8722.7910.159.87
EV/EBITDA3.103.105.043.573.14
P/B0.700.700.830.930.91
Growth & Yield
Revenue Growth-1.3%-1.3%-1.5%2.8%—
EPS Growth77.4%77.4%-59.9%7.5%—
Dividend Yield1.6%1.6%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

0.6%

fácil

EPS terminal req.

$2.08

Spread vs growth

76.8%

5Y implied EPS CAGR

4.2%

fácil

EPS terminal req.

$2.51

Spread vs growth

73.1%

10Y implied EPS CAGR

7.1%

razonable

EPS terminal req.

$4.04

Spread vs growth

70.3%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -6.7%

Total return

-6.7%

Start / end P/E

22.2x → 11.5x

EPS bridge

1.15 → 2.04

Residual

-37.3%

EPS growth+77.4%
Multiple rerating-48.3%
Dividend+1.6%
Residual / FX / buybacks / cross-term-37.3%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.